Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

Archives of Neurology

Volumn 54, Issue 5, 1997, Pages 531-533

  Mohr, David C ^a,b   Goodkin, Donald E ^a   Likosky, William ^c   Gatto, Nicole ^a   Baumann, Kristen A ^b   Rudick, Richard A ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PALO ALTO UNIVERSITY   (United States)

^c KAISER PERMANENTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; INTERFERON BETA SERINE;

ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY;

EID: 0030912908     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550170015009     Document Type: Article

References (10)

1. Paty DW, Li DKB, UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis, Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43:662-667.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing- remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
3. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995;37:611- 619.
4. Goodkin DE. Interferon beta treatment for multiple sclerosis: persisting questions. Multiple Sclerosis. 1996;1:321-324.
5. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Multiple Sclerosis. 1996;2:222-226.
6. Neilley LK, Goodin DS, Goodkin DE, Mohr DC, Hauser SL. Side effect profile of interferon beta 1-b (Betaseron). Neurology. 1996;46:552-554.
7. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol. 1983;13:227-231.
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1422-1427.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association; 1994.
10. Sherbourne CD, Wells KB, Hays RD, Rogers W, Burnam MA, Judd LL. Sub- threshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. Am J Psychiatry. 1994; 151:1777-1784.